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ivalirudin in Acute
yocardial Infarction:
Primum Non Nocere”
he Eternal Dilemma: Balancing Risks and
enefits in High-Risk Patients*
ernando Alfonso, MD, PHD, Manuel Paulo, MD
adrid, Spain
rimary angioplasty has been enthroned as the cornerstone
f therapy in patients with ST-segment elevation myocar-
ial infarction (STEMI) (1–3). In this scenario, coronary
tenting is systematically offered. While drug-eluting stents
DES) are becoming increasingly used in STEMI patients
ecause of their superior efficacy profile (1), safety concerns
emain, and bare-metal stents (BMS) are still preferred by
ome investigators in this highly thrombogenic milieu (3).
See page 796
djuvant pharmacological therapy remains another critical
ssue (1–3). The unprecedented advances in antithrombotic
herapy occurring in the last decade have led to dramatic
mprovements in reperfusion success, both at the epicardial
nd microvascular level, and more importantly, to superior
linical outcomes (1–4). However, the aggressive antiplate-
et therapies recommended for the highly instrumented
TEMI patients may act as a double-edged sword, leading
o increased hemorrhagic complications (1,2). Currently,
ajor bleeding is feared as 1 of the most important
oncardiac complication in these patients (4,5). In fact, not
nly anemia and bleeding but also transfusion requirement
ave been independently associated with major adverse
vents and mortality after coronary interventions (4,5). In
TEMI patients in particular, prevention of bleeding
mainly iatrogenic and related to the femoral access) is
urrently considered of paramount importance (4,5). Of
nterest, recent studies suggest that bivalirudin is not only
niquely safe but also cost effective in patients with a high
leeding risk (6).
Editorials published in the JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From Interventional Cardiology, Cardiac Department, Cardiovascular Institute,w
an Carlos University Hospital, Madrid, Spain. The authors have reported that they
ave no relationships to disclose.Therefore, further insights into the optimal adjuvant
ntiplatelet and antithrombotic regimens are urgently re-
uired to refine clinical practice in this challenging setting.
n this issue of JACC: Cardiovascular Interventions, a report
rom the HORIZONS-AMI (Harmonizing Outcomes
ith RevasculariZatiON and Stents in Acute Myocardial
nfarction) investigators (7) suggests that for “high-risk”
TEMI patients undergoing primary interventions, biva-
irudin reduces both mortality and recurrent myocardial
nfarction as compared with unfractionated heparin (UFH)
lus glycoprotein IIb/IIIa inhibitors (GPI).
he HORIZONS-AMI in perspective. Bivalirudin is especially
ttractive for STEMI patients undergoing primary angio-
lasty procedures. A retrospective study suggested that,
hen GPI are not used in this scenario, both bivalirudin and
FH showed equivalent efficacy and safety profiles (8).
owever, the benefits of GPI are well established for these
atients, despite the increase in bleeding risks (9). Of note,
or patients undergoing primary angioplasty, the prognostic
mplications of major bleeding are as important as reinfarc-
ion (1,2,4). The large HORIZONS-AMI trial provided
mportant novel evidence for the management of patients
ith STEMI undergoing primary interventions (1,2). The 2
oprimary end points of this trial were: 1) major bleeding;
nd 2) a combination of major bleeding and net adverse
linical events (including death, reinfarction, ischemia-
riven target vessel revascularization, and stroke) (1,2). The
ORIZONS-AMI study demonstrated that bivalirudin
ompared with UFHGPI decreased major bleeding and,
mportantly, 30-day and 1-year mortality (1). Bivalirudin
lso reduced late (30 days) cardiac mortality and reinfarc-
ion rates (2). An increased risk of acute stent thrombosis
pre-specified event) was initially detected in the bivalirudin
roup, but this risk signal disappeared at 30 days and 1 year
1,2). Since then, a major change in the landscape has
ccurred for STEMI patients, and many investigators con-
idered bivalirudin monotherapy as the standard of care
uring primary angioplasty procedures. However, economic
actors, prevailing doubts regarding efficacy, and a high use
f the radial artery access (10), together with “unscientific”
eluctance to change, remain barriers preventing a wider
tilization of this new agent during primary interventions in
any countries.
ontributions of the present study. The objective of the
urrent study by Parodi et al. (7) was to assess the relation-
hip between 1-year mortality and baseline patient risk.
ccordingly, the previously validated CADILLAC (Con-
rolled Abciximab and Device Investigation to Lower Late
ngioplasty Complications) risk score (11) was used to
lassify STEMI patients into low (1,522; 60%), intermedi-
te (531; 21%), and high risk (477; 19%). Interestingly, in
he high-risk subset, bivalirudin significantly reduced 1-year
ortality and recurrent myocardial infarction as compared
ith UFHGPI. These findings are of major clinical
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804nterest and reinforce the evidence supporting the value of
ivalirudin in STEMI patients. However, some method-
logical issues should be discussed.
First, although the benefit found for high-risk patients
as robust and unquestionable, no apparent efficacy benefit
ould be demonstrated for patients with low to intermediate
isk who actually accounted for 81% of patients in the trial
7). Thus, further studies should elaborate on the potential
alue bivalirudin in “unselected” real world patients with
TEMI.
Second, subgroup analyses tend to identify major benefits
n highly selected patient cohorts. In this situation, the
otential for bias or chance findings persists despite carefully
djusting for multiple testing. This potential is relevant
onsidering that even the main trial was unpowered to
etect reductions in mortality (although actually this was the
ase) (1,7).
Third, the reduction of bleeding complications with
ivalirudin was only significant in the low-risk group, and
hat may be perceived as counterintuitive. Considering the
ADILLAC risk score, one would anticipate that bleeding
isks would also be higher in high-risk patients and that, for
his subset, bivalirudin would be particularly effective. Sam-
le size constraints may explain this apparent paradox
ecause, actually, bivalirudin decreased bleeding estimates
cross all risk strata, although the difference was only
tatistically significant for low-risk patients, who accounted
or 60% of the population (7). The finding of a distinct
reatment effect depending on the selected outcome (death/
yocardial infarction versus bleeding) led these investigators to
ypothesize that among high-risk patients, the mortality re-
uction induced by bivalirudin cannot be solely explain by its
ffects on bleeding. Further, two-thirds of patients assigned to
ivalirudin received upfront UFH and a 600-mg clopidogrel
oading dose, and 7.5% of patients eventually received GPI (1).
hether these adjuvant strategies impacted in the outcome of
igh-risk patients remains unclear.
Fourth, the 2 strategies concurrently examined by the
ORIZONS-AMI factorial design (DES/BMS and biva-
irudin/UFHGPI) have major economic implications (1).
onsidering than DES and bivalirudin were demonstrated to
e superior to their comparators, information on long-term
ost-effectiveness, particularly in high-risk patients, would have
een of major interest, and warrants additional studies.
Fifth, although the value of the CADILLAC risk score
as been established (11), some of the requested items were
ot available in the HORIZONS-AMI study. Nearly one-
hird of patients (1,072) could not be risk stratified accord-
ng to this score because of missing data, mainly left
entricular angiography (7). Whether noninvasive assess-
ent of left ventricular function may be used as a surrogate
or angiographic ejection fraction, without affecting the
redictive value of the model, remains undefined. Besides, it
emains likely that the number of unclassifiable patients aould be higher during routine clinical practice than in a
andomized clinical trial. Furthermore, major differences
ere found between patients included in the present analysis
nd those unclassifiable. Indeed, “excluded” patients had a
isk marginally higher than that seen in the CADILLAC
tudy-derived “intermediate risk” subgroup (7).
Last but not least, in the HORIZONS-AMI study,
mergency coronary angiography was performed after ran-
omization to the corresponding antithrombotic therapy,
hich was started in the emergency room (1). However, of
he 7 variables used by the CADILLAC risk score, 4 are
eadily available before catheterization (age, anemia, renal
ailure, and Killip class), but 3 of them (left ventricular
jection fraction, multivessel disease, and final TIMI
Thrombolysis In Myocardial Infarction] flow grade) can only
e identified during or after the procedure, once the selection
f the antithrombotic strategy may have been made. This may
e considered as a caveat of this score for the selection of
atients most likely to benefit from bivalirudin therapy. These
otential limitations notwithstanding, the current study ex-
ends our knowledge and provides strong evidence in favor of
ivalirudin for high-risk STEMI patients (7).
ubgroup analyses: is the devil in the detail? The present
tudy represents a post-hoc subgroup analysis of the large
ORIZONS-AMI trial (7). Most subgroup analyses are
erformed from negative trials to identify patient subsets
ith potential clinical benefits. Therefore, attempts to
dentify the cohort of patients experiencing most of the
enefit from a positive trial deserve special recognition, and
he authors should be commended for this scientific en-
eavor. Conventional wisdom suggests that in randomized
linical trials, only the primary end point should be consid-
red to generate evidence-based scientific knowledge. This
ppears to be an adequate premise, considering that the
rimary end point determines the sample size calculation
equired to address the study’s hypothesis. Accordingly, the
dditional information obtained by pre-specified secondary
nd points, pre-defined subgroup analyses, and post-hoc
tudies (theoretically in decreasing order of scientific merit)
hould be considered as exploratory or hypothesis generat-
ng. However, is it all that simple?
Most current cardiovascular trials select composite end
oints as the primary outcome measure (12,13). Composite
nd points are highly effective to reduce sample size require-
ents, to avoid bias of competitive risks, and to assess the net
ffect of competing interventions. However, when significant
eterogeneity exists among their individual components (re-
arding clinical relevance, number of events, and magnitude of
reatment effect), the risk of misinterpretation increases
12,13). Some of these occurred in the HORIZONS-AMI
tudy. Would any patient or physician consider stroke and
leeding of similar relevance? As in most randomized clinical
rials, frequencies of individual events were largely different,
nd the effect of interventions varied among the components of
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805he combined end point. For instance, in this substudy (7) and
n the main HORIZONS-AMI trial (1,2), there was a
onsignificant trend for higher revascularization rates after
ivalirudin, among non–high-risk patients and among all
atients, respectively. Similarly, although from a different
linical setting, a signal for a higher rate of myocardial
nfarction after bivalirudin was detected in the ISAR-
EACT-3 (Intracoronary Stenting and Antithrombotic
egimen-Rapid Early Action for Coronary Treatment-3)
tudy and in a recent meta-analysis (14,15). If that were the
ase, the benefits of bivalirudin in reducing bleeding risks
ight be offset by a lower efficacy to prevent myocardial
nfarction (14,15). Under these circumstances, our confidence
o assess the real treatment effect by exclusively assessing the
esults of the combined primary end point is limited (12,13). It
s precisely in this context where subgroup analyses emerge as
powerful tool to fully characterize clinical factors significantly
ffecting treatment effects (12,13). Thus, the current analysis of
he HORIZONS-AMI trial provides scientifically valuable,
ovel, and unique insights that help to further refine interven-
ions in high-risk patients with STEMI.
inal remarks. The eternal therapeutic dilemma, balancing
isks and benefits for high-risk patients, remains unresolved.
s doing more good than harm better than primum non
ocere? Nowadays, costs should also be included in the
quation. When analyzing results of interventions in high-
isk patients, safety issues are of paramount importance, and
herefore, complications and their potential causes should be
arefully collected, openly disclosed, and critically scruti-
ized. Primum non nocere (first, not to harm) and secundus,
pinio vulnero (second, report the harm) may, therefore, be
qually important. When adequately performed, subgroup
nalyses provide unique insights not available by other
ethods. The HORIZONS-AMI study strictly adhered to
hese general principles and provided adequate guidance to
ptimize interventions in high-risk STEMI patients. For
hese patients, bivalirudin appears to be not only safer but
lso more effective than standard antithrombotic strategies
nd, therefore, should be considered the preferred option.
urther investigation is now warranted to assess the value of
ivalirudin for patients receiving novel, more predictable,
nd potent antiplatelet agents.
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